菌异生物代谢的最新进展:酶和应用
Mohd Faheem Khan1, Carina Hof1, Patricie Niemcová1
1UCD School of Biomolecular and Biomedical Science, University College Dublin, Belfield, Dublin 4, Ireland.
World journal of microbiology & biotechnology
|September 1, 2023
概括
菌有效地转化各种化合物使用酶,如laccases. 本综述探讨了药物和污染物的真菌代谢,强调了生物修复和生物催化剂的潜力.
科学领域:
- 环境微生物学环境微生物学
- 生物技术是生物技术.
- 生物化学 生物化学
背景情况:
- 菌类拥有多用途的酶 (乳酶,过氧酶,细胞染色体P450),使许多化合物的生物转化成为可能.
- 菌类的新陈代谢对于排毒天然和异生物物质至关重要,包括药品和环境污染物.
研究的目的:
- 审查了解药物和污染物的真菌代谢的最新进展.
- 为了确定参与真菌对外生态生物转化中的关键酶.
- 讨论真菌及其酶在生物修复和生物催化剂中的应用.
主要方法:
- 最近科学出版物的文献综述.
- 在异生物代谢中对真菌酶机制的分析.
- 综合有关真菌生物转化通路的信息.
主要成果:
- 菌代谢广泛的异生菌,包括染料,农业化学品和和多化基物质 (PFAS).
- 乳酶,过氧酶和P450细胞染色体是调解这些转换的关键酶.
- 最近的研究已经阐明了特定的代谢途径和酶功能.
结论:
- 菌酶为污染环境的生物修复提供了显著的潜力.
- 菌及其酶是生产重要化学化合物的宝贵生物催化剂.
- 对真菌异生菌代谢的持续研究可以推动环境和工业生物技术的创新.
相关概念视频
Drug Biotransformation: Overview
2.5K
Pharmaceutical substances known as xenobiotics are predominantly lipophilic and nonionized. This enables them to permeate lipid bilayers, such as cell membranes, and interact with intracellular target receptors. Lipophilic drugs have an advantage in crossing biological barriers and reaching their intended sites of action. However, lipophilic drugs often have a restricted capacity for renal expulsion or elimination from the body. When these drugs enter the kidneys and undergo glomerular...
2.5K
Overview of Fungi
49
Fungi are a diverse group of eukaryotes more closely related to animals than other eukaryotes. Fungal cell walls comprise chitin, a polysaccharide that provides structural strength, and glucans, which contribute to flexibility and integrity. Other polysaccharides, such as mannans and galactosans, may supplement or replace chitin in some fungi. These adaptations, along with their preference for acidic environments and tolerance for high osmotic pressure, enable fungi to thrive in various...
49
Factors Affecting Drug Biotransformation: Biological
177
Biological factors significantly impact drug metabolism, influencing drug clearance, efficacy, and potential toxicity.
Species differences: Variations in enzyme systems across species can cause disparities in drug metabolism. For instance, humans may metabolize certain drugs faster than rodents, altering therapeutic effects.
Strain differences: Genetic variations within a species can result in differing enzyme activity, impacting drug response and toxicity. For example, some mouse strains may...
Species differences: Variations in enzyme systems across species can cause disparities in drug metabolism. For instance, humans may metabolize certain drugs faster than rodents, altering therapeutic effects.
Strain differences: Genetic variations within a species can result in differing enzyme activity, impacting drug response and toxicity. For example, some mouse strains may...
177
Factors Affecting Drug Biotransformation: Physicochemical and Chemical Properties of Drugs
279
A drug's physicochemical properties fundamentally influence its metabolism. For instance, a drug's molecular size and shape critically determine its interaction with enzymes and transporters — larger drugs may face difficulty reaching enzyme active sites, altering their metabolic pathways. The pKa of a drug, which establishes its ionization state, can impact its solubility and absorption, thereby influencing metabolism.
The drug's acidity or basicity is essential in...
The drug's acidity or basicity is essential in...
279
Fungal Group Zygomycota
42
Zygomycota, previously classified as a distinct fungal group, are primarily terrestrial, saprophytic molds that play a crucial role as decomposers. Recent phylogenetic studies have revealed that these fungi are now divided into two major clades — Mucoromycota, which includes many symbiotic species, and Zoopagomycota, which primarily consists of parasitic and pathogenic fungi. These groups exhibit distinct ecological roles and reproductive strategies while sharing key structural and...
42
Drug Metabolism: Phase II Reactions
3.9K
Phase II reactions are essential for the detoxification and elimination of drugs from the body. These reactions involve the conjugation of parent drugs or their phase I metabolites with endogenous molecules, resulting in more hydrophilic drug conjugates. The primary conjugation reactions in this phase are sulfation and glucuronidation. Both sulfation and glucuronidation typically produce biologically inactive metabolites. However, in some cases involving prodrugs, active metabolites may be...
3.9K


